iX Biopharma Ltd logo

40V

SGX

iX Biopharma Ltd

Health CareSingapore

Financial Summary

MetricFY20FY17
Revenue$0$15.0M
EBITDA--
Net Profit$59.7M$0
EPS--
DPS--

Balance Sheet

Total Assets$63.6M
Total Liabilities-
Equity$62.9M
Net Debt$-42.2M
Cash$42.8M
NTA/Share-

FY20

Price Chart

Insufficient price data

Key Metrics

P/E Ratio-
P/B Ratio1.22
EV/EBITDA-1.64
Dividend Yield-
ROE-25.1%
ROA-15.2%
Net Margin0.0%
Debt/Equity0.01
Net Debt/EBITDA-
FCF Yield-

Governance Score

-

SGX Code of Corporate Governance

StocksSG provides data for informational purposes only. This is not financial advice. Information may contain errors or be outdated. Always verify data independently and consult a licensed financial adviser before making investment decisions.

Data sources · Full disclaimer